search
Back to results

Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
Over-encapsulated 10 mg amlodipine besylate tablet
Matched placebo capsule for over-encapsulated celecoxib capsule
Over-encapsulated 200 mg celecoxib capsule
Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Sponsored by
Kitov Pharmaceuticals, Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring High blood pressure, Systolic blood pressure, Diastolic blood pressure, Antihypertensive

Eligibility Criteria

40 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult 40 to 75 years of age
  2. Newly diagnosed hypertension that requires chronic pharmacological therapy. Specifically, the subject must meet both of the following criteria:

    1. Resting systolic BP ≥140 mmHg and ≤179 mmHg (where resting is defined as supine for at least 10 minutes with minimal interaction) at Initial Screening Visit
    2. SBPday >135 mmHg at Baseline Visit (Day 0)
  3. Body Mass Index of 18.5 to 34.9 kg/m2
  4. Healthy (other than hypertension) as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests
  5. A negative pregnancy test at Screening
  6. Both males and women of child bearing potential agree to use adequate contraceptive methods while on study (from Screening through final study visit)
  7. Able to comprehend and sign an informed consent form

Exclusion Criteria:

  1. Resting systolic BP >179 mmHg or a resting diastolic BP >110 mmHg at Screening (where resting is defined as supine for at least 10 minutes with minimal interaction) or SBP24h >169 mmHg or DBP24h >110 mmHg at randomization
  2. SBPday ≤135 mmHg at baseline (Day 0)
  3. Weight <55 kg
  4. Fragile health
  5. Evidence of clinically significant findings on screening evaluations (clinical, laboratory, and ECG) which, in the opinion of the Investigator would pose a safety risk or interfere with appropriate interpretation of safety data
  6. Current or recent history (within 4 weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection
  7. Current clinically significant viral infection
  8. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin
  9. Major surgery within 4 weeks prior to Screening
  10. Presence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn's disease or chronic pancreatitis)
  11. Active peptic ulceration or history of gastrointestinal bleeding
  12. History of myocardial infarction, congestive heart failure, or stroke
  13. Any current cardiovascular disease
  14. History of psychotic disorder
  15. History of alcoholism or drug addiction or current alcohol or drug use that, in the opinion of the Investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations
  16. History of any illicit drug use within one year prior to Screening
  17. Positive drug screen at Screening. A positive drug screen for opiates only (with all other drug tests negative) will not be a basis for exclusion if the subject took over-the-counter narcotics as indicated on the product label within 24 hours prior to the drug screen
  18. Current treatment or treatment within 30 days prior to first dose of study drugs with another investigational drug or current enrollment in another clinical trial
  19. Current treatment or treatment within 30 days prior to first dose of study drugs with an NSAID or systemic corticosteroid
  20. Known history of human immunodeficiency virus, hepatitis B, or hepatitis C
  21. Known hypersensitivity to amlodipine or celecoxib
  22. Known hypersensitivity to the inactive ingredients in the over-encapsulated study drugs
  23. Asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase-2 inhibitors
  24. Subjects who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule and study evaluations
  25. Pregnant or lactating
  26. Unable to correctly use ambulatory blood pressure monitor after instruction on its use
  27. Subjects with Child-Pugh Class B or C cirrhosis;
  28. Subjects currently taking a calcium channel blocker for any reason including angina. Subjects will not be withdrawn from these drugs to be enrolled in the trial
  29. Creatinine clearance <50 ml/min as estimated by the Cockroft-Gault equation
  30. Known cytochrome P450 2C9 poor metabolizer
  31. Subjects with allergy or hypersensitivity to sulfonamides

Sites / Locations

  • Celerion
  • The Medicines Evaluation Unit Ltd.
  • Reading Clinical Research Aspect
  • Synexus Merseyside Clinical Research Centre
  • Oldfield Surgery
  • Rowden Surgery
  • Synexus Midlands Clinical Research Centre
  • Synexus Scotland Clinical Research Centre
  • Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London
  • Reading Clinical Research Aspect

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Placebo Comparator

Sham Comparator

Arm Label

Amlodipine+Celecoxib

Amlodipine+Placebo

Placebo+Celecoxib

Placebo+Placebo

Arm Description

Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks

Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks

Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks

Outcomes

Primary Outcome Measures

Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint
Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)
Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug [i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug].

Secondary Outcome Measures

Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)
Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)
Mean Non-transformed Amlodipine Plasma Concentration
Mean Non-transformed Celecoxib Plasma Concentration
Mean Log-transformed Amlodipine Plasma Concentration
Mean Log-transformed Celecoxib Plasma Concentration
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint

Full Information

First Posted
June 20, 2014
Last Updated
September 11, 2018
Sponsor
Kitov Pharmaceuticals, Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02172040
Brief Title
Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Official Title
A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
June 26, 2014 (Actual)
Primary Completion Date
November 19, 2015 (Actual)
Study Completion Date
November 19, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kitov Pharmaceuticals, Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to evaluate the effect of celecoxib on the efficacy and safety of amlodipine besylate in subjects with newly diagnosed hypertension requiring antihypertensive therapy. This study was conducted to support a future marketing application for KIT-302. Kitov Pharma Ltd. (Kitov) is developing KIT-302, an oral fixed combination drug product (FCDP) consisting of the calcium channel blocker amlodipine besylate and the nonsteroidal anti-inflammatory drug (NSAID) celecoxib, as a "convenience reformulation" FCDP to facilitate and improve patient compliance with the once a day (qd) administration of its individual components, amlodipine and celecoxib. The formulation of KIT-302 consists of amlodipine besylate and celecoxib co-formulated in a single immediate release tablet. However, for this study, two separate capsules were utilized: one containing a commercial celecoxib capsule (Celebrex®) or matched placebo capsule and one containing a commercial amlodipine besylate tablet (Norvasc®) or matched placebo tablet. The study hypothesis was that treatment with the amlodipine besylate containing capsule plus the celecoxib containing capsule would reduce blood pressure (BP) in subjects with hypertension with an efficacy that is not substantially inferior to the effect of amlodipine besylate alone (i.e., the amlodipine containing capsule plus the matched placebo for the celecoxib capsule). The United States (US) Food and Drug Administration (FDA) recently approved KIT-302, under the brand name Consensi® (amlodipine and celecoxib) tablets [New Drug Application (NDA) 210045] for the following indication: "patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions."

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
High blood pressure, Systolic blood pressure, Diastolic blood pressure, Antihypertensive

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
152 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Amlodipine+Celecoxib
Arm Type
Experimental
Arm Description
Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Arm Title
Amlodipine+Placebo
Arm Type
Active Comparator
Arm Description
Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Arm Title
Placebo+Celecoxib
Arm Type
Placebo Comparator
Arm Description
Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Arm Title
Placebo+Placebo
Arm Type
Sham Comparator
Arm Description
Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Intervention Type
Drug
Intervention Name(s)
Over-encapsulated 10 mg amlodipine besylate tablet
Other Intervention Name(s)
Norvasc
Intervention Description
Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
Intervention Type
Drug
Intervention Name(s)
Matched placebo capsule for over-encapsulated celecoxib capsule
Other Intervention Name(s)
Placebo
Intervention Description
Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Intervention Type
Drug
Intervention Name(s)
Over-encapsulated 200 mg celecoxib capsule
Other Intervention Name(s)
Celebrex
Intervention Description
Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
Intervention Type
Drug
Intervention Name(s)
Matched placebo capsule for over-encapsulated amlodipine besylate tablet
Other Intervention Name(s)
Placebo
Intervention Description
Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
Primary Outcome Measure Information:
Title
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Primary Endpoint
Time Frame
Baseline and 2 weeks
Title
Frequency of Adverse Events (Number of Participants Affected/Number of Participants at Risk)
Description
Including any untoward medical occurrence in a participant administered study drug, which do not necessarily have a causal relationship with the study drug [i.e., any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug, whether or not related to the study drug].
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Mean Change in Average 24-hour Ambulatory Systolic Blood Pressure (SBP24h)
Time Frame
Baseline and 2 weeks
Title
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Systolic Blood Pressure (SBPnight)
Time Frame
Baseline and 2 weeks
Title
Mean Change in Average 24-hour Ambulatory Diastolic Blood Pressure (DBP24h)
Time Frame
Baseline and 2 weeks
Title
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Diastolic Blood Pressure (DBPday)
Time Frame
Baseline and 2 weeks
Title
Mean Change in Average Night-time (01:00 to 06:00) Ambulatory Diastolic Blood Pressure (DBPnight)
Time Frame
Baseline and 2 weeks
Title
Mean Non-transformed Amlodipine Plasma Concentration
Time Frame
24 hours post-dose on Day 14
Title
Mean Non-transformed Celecoxib Plasma Concentration
Time Frame
24 hours post-dose on Day 14
Title
Mean Log-transformed Amlodipine Plasma Concentration
Time Frame
24 hours post-dose on Day 14
Title
Mean Log-transformed Celecoxib Plasma Concentration
Time Frame
24 hours post-dose on Day 14
Title
Mean Change in Average Daytime (9:00 to 21:00) Ambulatory Systolic Blood Pressure (SBPday) - Secondary Endpoint
Time Frame
Baseline and 2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult 40 to 75 years of age Newly diagnosed hypertension that requires chronic pharmacological therapy. Specifically, the subject must meet both of the following criteria: Resting systolic BP ≥140 mmHg and ≤179 mmHg (where resting is defined as supine for at least 10 minutes with minimal interaction) at Initial Screening Visit SBPday >135 mmHg at Baseline Visit (Day 0) Body Mass Index of 18.5 to 34.9 kg/m2 Healthy (other than hypertension) as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests A negative pregnancy test at Screening Both males and women of child bearing potential agree to use adequate contraceptive methods while on study (from Screening through final study visit) Able to comprehend and sign an informed consent form Exclusion Criteria: Resting systolic BP >179 mmHg or a resting diastolic BP >110 mmHg at Screening (where resting is defined as supine for at least 10 minutes with minimal interaction) or SBP24h >169 mmHg or DBP24h >110 mmHg at randomization SBPday ≤135 mmHg at baseline (Day 0) Weight <55 kg Fragile health Evidence of clinically significant findings on screening evaluations (clinical, laboratory, and ECG) which, in the opinion of the Investigator would pose a safety risk or interfere with appropriate interpretation of safety data Current or recent history (within 4 weeks prior to Screening) of a clinically significant bacterial, fungal, or mycobacterial infection Current clinically significant viral infection History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin Major surgery within 4 weeks prior to Screening Presence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn's disease or chronic pancreatitis) Active peptic ulceration or history of gastrointestinal bleeding History of myocardial infarction, congestive heart failure, or stroke Any current cardiovascular disease History of psychotic disorder History of alcoholism or drug addiction or current alcohol or drug use that, in the opinion of the Investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations History of any illicit drug use within one year prior to Screening Positive drug screen at Screening. A positive drug screen for opiates only (with all other drug tests negative) will not be a basis for exclusion if the subject took over-the-counter narcotics as indicated on the product label within 24 hours prior to the drug screen Current treatment or treatment within 30 days prior to first dose of study drugs with another investigational drug or current enrollment in another clinical trial Current treatment or treatment within 30 days prior to first dose of study drugs with an NSAID or systemic corticosteroid Known history of human immunodeficiency virus, hepatitis B, or hepatitis C Known hypersensitivity to amlodipine or celecoxib Known hypersensitivity to the inactive ingredients in the over-encapsulated study drugs Asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase-2 inhibitors Subjects who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule and study evaluations Pregnant or lactating Unable to correctly use ambulatory blood pressure monitor after instruction on its use Subjects with Child-Pugh Class B or C cirrhosis; Subjects currently taking a calcium channel blocker for any reason including angina. Subjects will not be withdrawn from these drugs to be enrolled in the trial Creatinine clearance <50 ml/min as estimated by the Cockroft-Gault equation Known cytochrome P450 2C9 poor metabolizer Subjects with allergy or hypersensitivity to sulfonamides
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
J. Paul Waymack, MD, ScD
Organizational Affiliation
Kitov Pharma Ltd
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Brendan Colgan, MD
Organizational Affiliation
Celerion
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Claire Kightley, MB
Organizational Affiliation
Reading Clinical Research Aspect
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Collier, MBBS, PhD, BSc
Organizational Affiliation
Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Paul Ivan, MBBS
Organizational Affiliation
Synexus Merseyside Clinical Research Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Veronika Horvathova, MD
Organizational Affiliation
Synexus Scotland Clinical Research Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Amit Mathew, MS, MBBS
Organizational Affiliation
Synexus Midlands Clinical Research Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alexander Thompson, MB, BS, DRCOG
Organizational Affiliation
Reading Clinical Research Aspect
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mohamed Okily, MB
Organizational Affiliation
Synexus Manchester Clinical Research Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Richard Gaunt, MB, ChB, MRCGP, DRCOG
Organizational Affiliation
Rowden Surgery
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Patrick Eavis, MBBS, DRCOG, DFFP, MRCGP
Organizational Affiliation
Oldfield Surgery
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Arjun Ravi, MBBS, MRCP
Organizational Affiliation
The Medicines Evaluation Unit Ltd.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Celerion
City
Belfast
State/Province
Antrim
ZIP/Postal Code
BT9 6AD
Country
United Kingdom
Facility Name
The Medicines Evaluation Unit Ltd.
City
Manchester
State/Province
Greater Manchester
ZIP/Postal Code
M23 9QZ
Country
United Kingdom
Facility Name
Reading Clinical Research Aspect
City
Ledbury
State/Province
Herefordshire
ZIP/Postal Code
HR8 2AA
Country
United Kingdom
Facility Name
Synexus Merseyside Clinical Research Centre
City
Liverpool
State/Province
Merseyside
ZIP/Postal Code
L22 0LG
Country
United Kingdom
Facility Name
Oldfield Surgery
City
Bath
State/Province
North East Somerset
ZIP/Postal Code
BA2 3HT
Country
United Kingdom
Facility Name
Rowden Surgery
City
Chippenham
State/Province
Wiltshire
ZIP/Postal Code
SN15 2SB
Country
United Kingdom
Facility Name
Synexus Midlands Clinical Research Centre
City
Birmingham
ZIP/Postal Code
B15 2SQ
Country
United Kingdom
Facility Name
Synexus Scotland Clinical Research Centre
City
Glasgow
ZIP/Postal Code
G20 0SP
Country
United Kingdom
Facility Name
Barts Health NHS Trust, William Harvey Heart Centre, Barts & The London, Queen Mary School of Medicine and Dentistry, Queen Mary, University of London
City
London
ZIP/Postal Code
EC1M 6BQ
Country
United Kingdom
Facility Name
Reading Clinical Research Aspect
City
Reading
ZIP/Postal Code
RG6 6BZ
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy

We'll reach out to this number within 24 hrs